Submission of outcome of Board Meeting held on November 4, 2026

November 4, 2026 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI -400 051 MUMBAI -400 001 Company Code No. AUROPHARMA Company Code No. 524804 Dear Sir / Madam, Sub: Outcome of the Board Meeting held on November 4, 2026 The Board of Directors of the Company at its meeting held today, November 4, 2026, has, inter alia, considered and approved: a) the standalone and consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Unaudited Financial Results of the Company along with the Limited Review Reports issued by the Statutory Auditors. b) the payment of interim dividend of 700% i.e. Rs.7.00 (Rupees seven only) per equity share of Re.1/- each on the equity share capital of the Company. The Company has fixed November 11, 2026, as the Record Date for the purpose of payment of Interim Dividend and the same will be paid on or before November 20, 2026. c) the proposal to file a Scheme of Amalgamation for merger of Auroactive Pharma Private Limited, wholly owned subsidiary of the Company with Apitoria Pharma Private Limited, wholly owned subsidiary of the Company, with Hon’ble NCLT, Hyderabad, that has been approved by the Board of Directors of the respective companies. d) the transfer of ownership of Auro Pharma LLC, Russia, from Auroactive Pharma Private Limited to Auropharm Overseas Limited, wholly owned subsidiaries of the Company that has been approved by the Board of Directors of the respective companies. Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044. Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana, India Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833 Email: info@aurobindo.com Website: www.aurobindo.com e) based on the recommendation of the Nomination and Remuneration/Compensation Committee and subject to the approval of the Members through Postal Ballot, the re-appointment of Mr. Mangalam Ramasubramanian Kumar (DIN 03628755) as a Director (Non-executive and Independent) of the Company for the second term of 5 (five) years with effect from April 1, 2027. His first term as Non- executive and Independent Director is completing on March 31, 2027. The Board meeting commenced at 4:15 p.m. and concluded at 6:00 p.m. Please take the information on record. Yours faithfully, For AUROBINDO PHARMA LIMITED B. Adi Reddy Company Secretary Enclosures: as above. Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044. Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana, India Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833 Email: info@aurobindo.com Website: www.aurobindo.com AUROBINDO PHARMA LIMITED (CiN -L24239TG1986PLC015190) WNW aurobindo.com Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad -500 038, India Tel: +91 (40) 66721200; Fax: +91 40 23741080; Email: info@aurobindo.com (All amounts are in ~ million, unless otherwise stated) STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30,2026 Quarter ended Half.E!ar ended Year ended Particulars 30.09.2026 30,06.2026 30.09.2025 30.09.2026 30.09.2025 31.03.L026 Unaudited Unaudited Unaudited Unaudited Unaudited Audited A Continuing Operations: 1 Revenue from operations (a) Net sales! income from operations 31,627.9 27,816.9 27,001.0 59,444.8 54,709.0 1,08,537.1 (b) Other operating income 145.4 178.2 298.3 323.6 558.6 1,1633 Total revenue from operations 31,773.3 27,995.1 27,2993 59,768.4 55,2676 1,09,700.4 2 Other income (a) Forei~n exchange gain (net) 221.0 729.9 591.5 950.9 9975 1,7907 Ib) Others 807.0 1,689.0 1,003.7 2,496.0 1,435.4 4,084.6 Total other income 1,028.0 2,418.9 1,595.2 3,446.9 2,432.9 5,875.3 3 Total income (1+2) 32,801.3 30,414.0 28,894_5 63,215.3 57,700.5 1,15,575.7 4 Expenses (a) Cost of materials consumed 13,809.7 12,888.9 12,385.1 26,698.6 25,740.7 52,200.9 (b) Purchase of stock-in-trade 13.5 - 10.5 13.5 10.5 49.0 (c) Changes in inventories of finished goods, stock·in-trade and work- 777.2 (480.5) 1,054.0 296.7 1,430.9 542.4 In-progress (d) Employee benefits expense 3,000.7 2,959.1 2,768.2 5,959.8 5,447.1 10,943.3 (e) Finance costs 480.9 470.7 574.4 951.6 1,174.4 2.130.7 (f) Depreciation and amortisation expenses 695.2 689.9 670.0 1,385.1 1,3259 2,676.0 (g) Other expenses 4,314.6 3,805.1 3,868,2 8,119.7 7,4828 15,037.4 Total expenses 23,091.S 20,333.2 21,330.4 43,425.0 42,612.3 83,579.7 5 Profit before exceptional items and tax from continuing operations (3- 9,709.5 10,080.8 7,564.1 19,790.3 15,088.2 31.996.0 6 Exceptional items (refer note 5) - - - 173.8 7 Profit before tax from continuing operations (5-6) 9,709.5 10,080.8 7,564.1 19,790.3 15,088.2 31,822.2 S Tax expense Current tax 2,477.4 2,715.0 1,744.8 5,192.4 3,627.4 7.512.3 Deferred tax (3.7) (6.4) (3.1) (10.1) 29.7 19.6 Total tax expense 2,473.7 2,708.6 1,741.7 5.182.3 3.657 1 7.531.9 9 Profit after tax from continuing operations (7-8) 7.235.8 7,372.2 5,822.4 14,60S.0 11.431.1 24,290.3 B Discontinued Operations: (Refer note 4) 10 Loss before tax from discontinued operations - - (11.3) - (34.5) (186.4) 11 Tax expense from discontinued operations - - (2.6) (8.4) (44.1) 12 Loss from discontinued operations (10-11) (8.7) (26.1) (142.3) 13 Profit after tax (9+ 12) 7,235.8 7.372.2 5.813.7 14,608.0 11,405.0 24,148.0 14 Other comprehensive income A) Items that will not to be reclassified subsequently to profit or loss: (a) Re-measurement of defined benefit liability (60.4) 3.6 (0.4) (56.S) (18.0) 14.5 (b) Income-tax relating to items that will not be reclassified to profit or 15.2 (0.9) 0.1 14.3 4.5 (3.7) loss B) Items that will be reclassified subsequently to profit or loss: a) Fair value change on derivatives designated as cash flow hedge Inet) 7S.0 - - 7S.0 - - b) Income-tax on items that will be reclassified subsequently to profit or (19.6) - (19.6) loss Total other comprehensive income/(Ioss) (net of tax) 13.2 2.7 (0.3) 15.9 (13.5) 10.8 15 Total comprehensive income (13+14) 7,249.0 7.374.9 5,813.4 14,623.9 11,391.5 24.158.8 16 Paid-up equity share capital (face value ~ 1 per share) 575.4 575.4 580.8 575.4 580.8 580.8 17 Other equity 2,26.596.1 18 Earnings per equity share from continuing operations (face value ~ 1 per (Not annuallsed) (Not annualised) (Not annualised) (Not annualised) (Not annualised (Annualised) sharel (a) Basic (in ~) 12.5S 12.75 10.02 25.33 19.68 41.83 (b) Diluted (in ~) 12.5S 12.75 10.02 25.33 19.68 41.83 19 Earnings per equity share from discontinued operations (face value ~ 1 (Not annualised) (Not annualised) (Not annualised) (Not annualised) (Not annualised (Annualised) Der share) (a) Basic (in ~) (0.01) (0.04) (0.25) (b) Diluted (in ~) (0.01) (0.04) (0.25) 20 Earnings per equity share for total operations (face value 'I: 1 per share) (Not annualised) (Not annualised) (Not annualised) (Not annualised) (Not annualised (Annualised) (a) Basic (in ~) 12.58 12.75 10.01 25.33 19.64 4158 bl Diluted (in ~) 12.5S 12.75 10.01 25.33 19.64 41.58 Page 1 of 4 Standalone Balance Sheet {All ~rnollnts are in '{ million. unless otherwise $laced 51. As at As at Particulars No. 30.09.2026 31.03.2026 Unaudited Audited ASSETS 1 Non-current assets Property. plant and equipment 23,783.0 23,177.6 Capital work-in-progress 2,240.6 2,285.5 Right-of-use assets 924.9 1,021.7 Goodwill 917.0 Oth [Showing first 8,000 characters — download PDF for full document]